Iadecola C, Zhang F
Department of Neurology, University of Minnesota Medical School, Minneapolis 55455, USA.
Am J Physiol. 1996 Oct;271(4 Pt 2):R990-1001. doi: 10.1152/ajpregu.1996.271.4.R990.
Inhibition of nitric oxide (NO) synthesis attenuates the hypercapnic cerebrovasodilation or the increases in cerebral blood flow (CBF) produced by acetylcholine (ACh), either topically applied or endogenously released in neocortex by stimulation of the basal forebrain cholinergic system. We investigated whether exogenous administration of NO, using NO donors, can reverse the attenuation of these responses by NO synthase (NOS) inhibitors. In halothane-anesthetized, ventilated rats the frontoparietal cortex was exposed and superfused with Ringer. CBF was monitored at the super fusion site by laser-Doppler flowmetry. The basal forebrain was stimulated (100 microA; 50 Hz) with microelectrodes stereotaxically implanted. Superfusion with the NOS inhibitor NG-nitro-L-arginine (L-NNA; 1 mM) reduced resting CBF (-38 +/- 2%; mean +/- SE) and attenuated the vasodilation elicited by hypercapnia (Pco2, 50-60 mmHg; -79 +/- 3%), ACh (10 microM; -83 +/- 7%), or basal forebrain stimulation (-44 +/- 2%) (P < 0.05, analysis of variance and Tukey's test). After L-NNA, topical application of 3-morpholinosydnonimine (SIN-1) (n = 7), S-nitroso-N-acetylpenicillamine (SNAP) (n = 6), or 8-bromoguanosine 3',5'-monophosphate (8-BrcGMP, n = 4) reestablished resting CBF (P > 0.05 from Ringer) and reversed the attenuation of the response to hypercapnia (P > 0.05 from Ringer). However, SIN-1 or SNAP failed to reverse the attenuation of the response to basal forebrain stimulation or topical ACh (P > 0.05 from L-NNA). After L-NNA, the NO-independent vasodilator papaverine (n = 4) reestablished resting CBF (P > 0.05 from Ringer) but failed to restore the hypercapnic vasodilation (P > 0.05 from L-NNA). The attenuation of hypercapnic response by the neuronal NOS inhibitor 7-nitroindazole was counteracted only partially by SIN-1 (n = 4) or 8-BrcGMP (n = 4). The data support the hypothesis that the vasodilation elicited by hypercapnia requires resting levels of NO for its expression, whereas the response to endogenous or exogenous ACh depends on agonist-induced NOS activation. In hypercapnia NO may act as a permissive factor by facilitating the action of other vasodilators, whereas in the vascular response initiated by ACh NO is likely to be the major mediator of smooth muscle relaxation.
抑制一氧化氮(NO)合成可减弱高碳酸血症性脑血管舒张,或减弱由乙酰胆碱(ACh)所产生的脑血流量(CBF)增加,ACh可局部应用,也可通过刺激基底前脑胆碱能系统在新皮质内源性释放。我们研究了使用NO供体外源性给予NO是否能逆转NO合酶(NOS)抑制剂对这些反应的减弱作用。在氟烷麻醉、机械通气的大鼠中,暴露额顶叶皮质并用林格液灌注。通过激光多普勒血流仪在灌注部位监测CBF。用立体定向植入的微电极刺激基底前脑(100微安;50赫兹)。用NOS抑制剂NG-硝基-L-精氨酸(L-NNA;1毫摩尔)灌注可降低静息CBF(-38±2%;平均值±标准误),并减弱高碳酸血症(Pco2,50 - 60毫米汞柱;-79±3%)、ACh(10微摩尔;-83±7%)或基底前脑刺激(-44±2%)所引起的血管舒张(方差分析和Tukey检验,P < 0.05)。在给予L-NNA后,局部应用3-吗啉代 sydnonimine(SIN-1)(n = 7)、S-亚硝基-N-乙酰青霉胺(SNAP)(n = 6)或8-溴鸟苷3',5'-单磷酸(8-BrcGMP,n = 4)可恢复静息CBF(与林格液相比,P > 0.05),并逆转对高碳酸血症反应的减弱(与林格液相比,P > 0.05)。然而,SIN-1或SNAP未能逆转对基底前脑刺激或局部应用ACh反应的减弱(与L-NNA相比,P > 0.05)。在给予L-NNA后,不依赖NO的血管舒张剂罂粟碱(n = 4)可恢复静息CBF(与林格液相比,P > 0.05),但未能恢复高碳酸血症性血管舒张(与L-NNA相比,P > 0.05)。神经元NOS抑制剂7-硝基吲唑对高碳酸血症反应的减弱仅被SIN-1(n = 4)或8-BrcGMP(n = 4)部分抵消。这些数据支持以下假说:高碳酸血症所引起的血管舒张在表达时需要静息水平的NO,而对内源性或外源性ACh的反应则依赖于激动剂诱导的NOS激活。在高碳酸血症中,NO可能通过促进其他血管舒张剂的作用而作为一个允许因子,而在由ACh引发的血管反应中,NO可能是平滑肌舒张的主要介质。